Caplin Point enters into an agreement with US based Fresenius Kabi

06 Apr 2015 Evaluate

Caplin Point Laboratories has entered into a license and distribution agreement with Fresenius Kabi USA, LLC, a Delaware Limited Liability Company.  Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialize the same in USA. This is a product specific agreement for United States of America. Currently two products are featuring in the contract.

Caplin Point has already received milestone payments for two products and the product development cum dossier preparation have just commenced.

Fresenius Kabi is one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.


Caplin Point Lab Share Price

1734.75 -6.50 (-0.37%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×